Designs for Health Oleoylethanolamide (OEA) is a practitioner-grade ingredient supplied exclusively for extemporaneous compounding. Featuring Trpti OEA™, this Australia-first formulation delivers a next-generation form of oleoylethanolamide, a naturally occurring lipid mediator produced in the small intestine. Enhanced with LipiSperse® delivery technology, this advanced OEA ingredient is designed to address the bioavailability challenges associated with standard OEA preparations.
Key Features
• Supplied for extemporaneous compounding only
• Features Trpti OEA™, a next-generation oleoylethanolamide
• OEA is an endogenous fatty acid amide produced in the small intestine
• Classified within the acylglycerol and N-acylethanolamine families
• LipiSperse® delivery technology for improved dispersion and absorption
• Research reference dose of 125 mg twice daily
• Vegan friendly
Why People Love It
Oleoylethanolamide (OEA) with Trpti OEA™ is valued for its advanced delivery system and high-quality raw material sourcing. The inclusion of LipiSperse® helps overcome traditional absorption limitations, making it a reliable choice for practitioners formulating precision-based compounded products.
Ingredients
• Trpti OEA™ (Oleoylethanolamide)
• LipiSperse® delivery technology